Business Wire

  1. Merck And Mayo Clinic Announce New Research And Development Collaboration To Support AI-Enabled Drug Discovery And Precision Medicine 2/18/2026

    Merck, known as MSD outside of the U.S. and Canada, and Mayo Clinic, the world's top-ranked hospital system, today announced a research and development agreement to apply artificial intelligence (AI), advanced analytics and multimodal clinical data to support drug discovery and development.

  2. U.S. Food And Drug Administration Accepts Bristol Myers Squibb's New Drug Application For Iberdomide In Patients With Relapsed Or Refractory Multiple Myeloma 2/17/2026

    Bristol Myers Squibb today announced that the U.S. Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) for iberdomide combined with standard treatment (daratumumab + dexamethasone - IberDd) in patients with relapsed or refractory multiple myeloma (RRMM).

  3. Harmony Biosciences Receives U.S. Food And Drug Administration Approval For WAKIX (pitolisant) For The Treatment Of Cataplexy In Pediatric Narcolepsy 2/17/2026

    Harmony Biosciences today announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental new drug application (sNDA) for WAKIX (pitolisant) tablets for the treatment of cataplexy in pediatric patients 6 years of age and older with narcolepsy.

  4. BostonGene Announces Strategic Collaboration With Daiichi Sankyo To Accelerate Drug Development Through AI-Driven Multimodal Analytics 2/17/2026

    BostonGene, the developer of the leading AI foundation model for tumor and immune biology, today announced a strategic collaboration with Daiichi Sankyo.

  5. Deciphera Pharmaceuticals Announces U.S. Food And Drug Administration Acceptance For Filing Of New Drug Application For Tirabrutinib In Patients With Relapsed Or Refractory PCNSL 2/17/2026

    Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) under the accelerated approval pathway for tirabrutinib, a highly selective irreversible, second generation Bruton tyrosine kinase inhibitor, for the treatment of relapsed or refractory primary central nervous system lymphoma (R/R PCNSL).

  6. Twist Bioscience Expands Antibody Discovery Offering With Bispecific Licensing Agreement 2/17/2026

    Twist Bioscience Corporation, a mid-cap growth and value biotech company, today announced that it has entered into a licensing agreement withInvenra Inc.

  7. Nuclera And Leadxpro Partner To Accelerate Structure-Based Drug Design For Complex Membrane Proteins 2/17/2026

    Nuclera, the biotechnology company enabling rapid access to high-quality proteins and leadXpro, a specialist in structure-based drug discovery for membrane proteins, today announced a scientific partnership.

  8. Precision BioSciences Receives U.S. FDA Clearance Of Investigational New Drug Application For First-In-Class PBGENE-DMD For Treatment Of Duchenne Muscular Dystrophy 2/11/2026

    Precision BioSciences, Inc., a clinical stage gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that the Company received a Study May Proceed notification from the U.S. Food and Drug Administration (FDA).

  9. Lantern Pharma To Present At The 7th Glioblastoma Drug Development Summit In Boston On February 17-19, 2026 2/10/2026

    Lantern Pharma Inc., a clinical-stage biopharmaceutical company leveraging artificial intelligence to accelerate oncology drug discovery and development, today announced that CEO and President Panna Sharma will present at the 7th Glioblastoma Drug Development Summit, February 17–19, 2026, in Boston, MA.

  10. U.S. Food And Drug Administration Accepts New Drug Application And Grants Priority Review For Takeda's Oveporexton (TAK-861) As A Potential First-In-Class Therapy For Narcolepsy Type 1 2/10/2026

    Takeda today announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) and granted Priority Review for oveporexton (TAK-861) for the treatment of narcolepsy type 1 (NT1).